WO2001074364A2 - A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease - Google Patents
A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease Download PDFInfo
- Publication number
- WO2001074364A2 WO2001074364A2 PCT/EP2001/003551 EP0103551W WO0174364A2 WO 2001074364 A2 WO2001074364 A2 WO 2001074364A2 EP 0103551 W EP0103551 W EP 0103551W WO 0174364 A2 WO0174364 A2 WO 0174364A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- galantamine
- day
- dose
- dosage
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the present invention relates to the use of an effective amount of galantamine for the production of a medicament for the treatment of Alzheimer's disease, wherein said treatment provides both symptomatic relief and also treats the underlying cause of the disease.
- Galantamine is known to be a reversible cholinesterase inhibitor that can be isolated from a number of different plant sources, including daffodil bulbs. Galantamine interacts competitively with the enzyme, acetylcholinesterase, and demonstrates a 10 to 50 fold selectivity for acetyl vs. butyryl cholinesterase.
- Galantamine has been used for the treatment of a number of chronic diseases, where lifelong treatment may be necessary.
- Galantamine has been shown to be effective in the treatment of Alzheimer's Disease (United States Patent 4,663,318).
- Alzheimer's disease The etiology of neuronal degeneration and associated cognitive impairment in Alzheimer's disease is not fully understood. However, three consistent neuropathological hallmarks have been identified: amyloid-rich senile plaques, tau-positive neurofibrillary tangles, and neuronal cell death.
- Methods of treating Alzheimer's disease include the use of therapeutic drugs for symptomatic relief of the cognitive symptoms of the disease.
- US Patent 5,962,535 acknowledged the shortcomings of the prior treatments and proposed the use of a pharmaceutical composition for treating or preventing Alzheimer's disease which comprises idebenone in combination with a compound having acetylcholinesterase inhibitory activity. According to this prior art, this combination of compounds produced clinical benefits not seen in previous treatments. Thus, there is a need for other therapeutic drugs for treating, preventing and inhibiting the progression of Alzheimer's disease by targeting the underlying cause of the disease.
- FIGURE 1 shows the mean change ( ⁇ SE) in ADAS-cog/11 from baseline to the end of the treatment period to the end of the washout period.
- FIGURE 2 shows the prior art results with donepezil hydrocliloride in a similar study.
- the present invention relates to the use of an effective amount of galantamine for the production of a medicament for treating, preventing and inhibiting the progression of Alzheimer's disease by targeting the underlying cause of the disease.
- Galantamine a tertiary alkaloid
- Galantamine has been isolated from the bulbs of the Caucasian snowdrops Galant ⁇ ms woronowi (Proskurnina, N. F. and Yakoleva, A. P. 1952, Alkaloids of Galanth s woronowi. II. Isolation of a new alkaloid. (In Russian.) Zh.Obschchei Khim. (J. Gen. Chem.) 22, 1899-1902). It has also been isolated from the common snowdrop Galanthus nivalis (Boit, 1954).
- Galantamine is a well-known acetylcholinesterase inhibitor which is active at nicotinic receptor sites but not at muscarinic receptor sites. It is capable of passing the blood-brain barrier in humans, and presents no severe side effects in therapeutically effective dosages.
- Galantamine has been used extensively as a curare reversal agent in anaesthetic practice in Eastern bloc countries (cf. review by Paskow, 1986) and also experimentally in the West (cf. Bretagne and Valetta, 1965: Wislicki, 1967; Consanitis. 1971). Galantamine has been marketed by the company Waldheim (Sanochemia protagonist) as
- galantamine we include within this term galantamine itself, derivatives and salts thereof, such as halides, for example galantamine hydrobromide.
- galantamine and derivates and salts thereof may be formulated according to convention methods of pharmacy, together where appropriate with one or more pharmaceutically acceptable carriers, excipients or diluents, as is known in the art.
- Such formulations can take the form of tablets, capsules, solutions, or lozenges, pessaries, creams, suppositories or transdermal formulations, depending on the route of administration.
- galantamine for example galantamine hydrobromide
- Galantamine hydrobromide is thought to increase the release of acetylcholine through a mechanism called allosteric modulation of the nicotinic receptors.
- galantamine hydrobromide binds to a site on the presynaptic nicotinic receptor, that is distinct from the acetylcholine- binding site, and evokes a change in the shape of the receptor.
- Such modulation is self-regulating, which produces overstimulation.
- the increased production of acetylcholine competitively inhibits the enzyme responsible for its breakdown, acetylcholinesterase.
- stimulation of presynaptic nicotinic receptors also increases the release of other neurotransmitters (such as glutamate) thought to play important roles in cognitive function.
- the impact of drug withdrawal was used as an indication of the impact of the drug on cognitive function. The expectation was that patients treated with galantamine, and then withdrawn from the drug would return to levels of cognitive function similar to those documented in the placebo group.
- a safe and effective amount of galantamine can be used for treating, preventing and inhibiting the progression of Alzheimer's disease by targeting the underlying cause of the disease.
- Precise dosage rates and regimes can be determined empirically by the medical practitioner, depending on individual circumstances. For example, if the compound is delivered orally, a daily dose of from about 1 mg to about 100 mg is effective. In a further example the compound can be delivered at about 5 mg to about 50 mg per day. In yet a further example the compound can be delivered at about 16 mg to about 32 mg per day. Precise daily dosages can be selected from 16 mg, 18 mg, 24 mg or 32 mg per day. It is preferred that the daily dosage be divided into two or three equal dosages.
- the patient is introduced to galantamine slowly from about 2 weeks to about 10 weeks, wherein the dose is increased over this period.
- the patient received a dose of about 8 mg/day for about 1 week, followed by a dose of about 16 mg/day for about 1 week, followed by a maintenance dose of about 24 mg/day thereafter.
- the patient received a dose of about 8 mg day for about 1 week, followed by a dose of about 16 mg/day for about 1 week, followed by a dose of about 24 mg day for about 1 week, followed by a maintenance dose of about 32 mg/day thereafter.
- the patient received a dose of about 8 mg day for from about 2 weeks to about 4 weeks, followed by a dose of about 16 mg/day for from about 2 weeks to about 4 weeks, followed by a maintenance dose of about 24 mg/day thereafter.
- the patient received a dose of about 8 mg/day for about 4 weeks, followed by a dose of about 16 mg/day for about 4 weeks, followed by a maintenance dose of about 24 mg/day thereafter.
- the patient received a dose of about 8 mg/day for from about 2 weeks to about 4 weeks, followed by a maintenance dose of about 16 mg/day thereafter.
- the patient received a dose of about 8 mg/day for about 4 weeks, followed by a maintenance dose of about 16 mg/day thereafter.
- EXAMPLES A six -week randomized withdrawal study compared withdrawal from a three month treatment with galantamine, to continued treatment with 24 mg or 32 mg galantamine (given in two equal doses), or continued treatment with a placebo.
- ADAS Alzheimer's Disease Assessment Scale
- ADAS-cog ADAS-cognitive scale
- the primary efficacy endpoints were the change from baseline ADAS-cog/11.
- the ADAS consists of two parts — a cognitive subscale and a behavioral subscale.
- the behavioral subscale was not be used in this study.
- the cognitive subscale, the ADAS— cog-11 comprises the following 11 items, with a score ranging from 0 to 70:
- the ADAS-cog/13 was used as a secondary variable.
- the ADAS-cog/13 subscale consisted of the 11 items in the ADAS-cog/11 subscale plus two new items, which were added to provide more information regarding the patient's status.
- This secondary variable with a score ranging from 0 to 85 contains the additional two items: Concentration and Distraction (0 to 5) and Delayed Word Recall (0 to 10).
- ADAS-cog/10 Object and Finger Naming (0 to 5) Commands (0 to 5) Constructional Kir (0 to 5)
- the memory ADAS cognitive subscale is the sum of the following three items (score range 0 to 32):
- the MMSE is a very brief test of cognitive functions including orientation to time and place, instantaneous recall, short-term memory, and ability to perform serial subtractions or reverse spelling, constructional capacities and the use of language.
- the MMSE score was derived from the sum of the points assigned to each completed task. A total possible score is 30. The MMSE was performed at visit l(screening).
- the primary efficacy parameter was the total score of the 11 cognitive items from the original ADAS cognitive subscale (ADAS-cog/11).
- the secondary efficacy parameters were ADAS cluster scores ADAS-cog/13, ADAS-cog/10, and ADAS-cog/mem, as well as the percentage of responders.
- the placebo group 47 patients, continued receiving the placebo.
- the galantamine group were divided into two groups. One group, 39 patients, were given a placebo in this withdrawal test, whereas the other group, 32 patients, continued receiving the dose of galantamine, 24mg/day or 32 mg/day, given in the earlier completed study. Ninety four percent of the patients completed the trail.
- Table 1 summarizes the demographics and baseline characteristics (from intake into the initial study) for all patients participating in this trial. Slightly more women (59%) than men (41%) participated in the trial. The majority (91 %) of patients were white, with an average age of 75 years and an average weight of 69 kg. These factors were well balanced across treatment groups, and no statistically significant differences were found among the three treatment groups. Table 1. Demographic and baseline disease characteristics for all patients
- the primary analysis was performed on ADAS data collected at Week 6 (traditional observed case) and compared to ADAS data collected at initial visit (primary) and baseline visit (secondary). Patients missing data for Week 6 were not included in the analysis. The primary comparison was between the PLA PLA group and the GAL PLA group in change from initial visit at Week 6.
- ADAS-cog/11 (Alzheimer's Disease Assessment Scale - Cognitive Subscale) was the total score of 11 cognitive items on the ADAS. The total score ranges from 0-70, with a higher score indicating a worsening of cognitive function. ADAS-cog/11 score was calculated only when all 11 items were available. Missing ADAS-cog/11 scores were not replaced or imputed due to the low missing rate.
- Table 5 presents the means and mean change from baseline (beginning of the initial study) for ADAS cluster scores at Week 6.
- Table 6 shows the mean changes from initial visit on ADAS individual item scores at Week 6. In general, no change from initial visit was seen in all of the groups.
- ADAS-cog/11 response Four definitions for ADAS-cog/11 response were used to summarize ADAS-cog/11 response data. Responder (0) was defined for those patients with no change or better ( ⁇ points improvement) on ADAS-cog/11 score. Similarly, responder (4) was for ⁇ 4 points improvement, responder (7) for >7 points improvement and responder (10) for >10 points improvement.
- the percentages are based on total number of patients who had an evaluation at the specific visit.
- the response data, from initial visit, at Week 6 shows that about 61% of PLA/PLA patients had no change or were improved in ADAS-cog/11 score, as compared to 47% in the GAIJPLA group and 55% in the GAIJGAL group.
- the use of higher cutoff points demonstrate that patients who received galantamine were higher responders than patients who only received placebo. Only fifteen percent of PLA/PLA group patients had ⁇ 4 points improvement in ADAS-cog/11 score at Week 6, as compared to 19% in the GAIJPLA group and 28% in the GAL/GAL group.
- response data for patients withdrawn from galantamine to placebo were intermediate between patients who remained on placebo and patients who remained on galantamine, for all four cutoff points.
- patients treated with galantamine for 3 months in a preceding double blind, flexible dose trial tended to have improved cognitive function (as measured by a reduction in ADAS-cog/11 score from baseline) compared to patients who had received placebo.
- ADAS-cog/11 scores for patients in the GAIJPLA group who had received galantamine for 3 months, then were withdrawn and placed on placebo for 6 weeks, were back to approximately the level of the original double-blind baseline.
- Patients in the PLA/PLA group who had received placebo during both the original treatment period and the withdrawal period, had ADAS-cog/11 scores that continued to increase, indicating a worsening in cognitive function.
- Patients in the GAIJGAL group, who had received galantamine during both the original treatment and the withdrawal period had ADAS-cog/11 scores that continued to decrease, indicating an improvement in cognitive function.
- results of the present invention contrast the results available in the prior art in a study using another cholinesterase inhibitor, donepezil hydrochloride.
- patients received either 5mg/day or 10 mg/day for a treatment period of 24 weeks, followed by a 6 week placebo washout period.
- the treatment group was indistinguishable from the group that received only placebo for the 30 week period.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01919406A EP1272190A2 (en) | 2000-04-03 | 2001-03-28 | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease |
AU2001246518A AU2001246518A1 (en) | 2000-04-03 | 2001-03-28 | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19426200P | 2000-04-03 | 2000-04-03 | |
US60/194,262 | 2000-04-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001074364A2 true WO2001074364A2 (en) | 2001-10-11 |
WO2001074364A3 WO2001074364A3 (en) | 2002-05-16 |
Family
ID=22716910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/003551 WO2001074364A2 (en) | 2000-04-03 | 2001-03-28 | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1272190A2 (en) |
AU (1) | AU2001246518A1 (en) |
CA (1) | CA2310990A1 (en) |
WO (1) | WO2001074364A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001074339A2 (en) * | 2000-04-03 | 2001-10-11 | Janssen Pharmaceutica N.V. | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
EP2213285A2 (en) * | 2003-12-19 | 2010-08-04 | Novartis AG | Use of sphingosine-1-phosphate (S1P) receptor agonists in combination with a second agent for the treatment of brain degenerative diseases |
US20180200259A1 (en) * | 2015-05-18 | 2018-07-19 | Synaptec Development Llc | GALANTAMINE CLEARANCE OF AMYLOID ß |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4663318A (en) | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
EP1133230A4 (en) | 1998-11-23 | 2004-05-26 | Bonnie M Davis | Dosage formulations for acetylcholinesterase inhibitors |
-
2000
- 2000-06-27 CA CA002310990A patent/CA2310990A1/en not_active Abandoned
-
2001
- 2001-03-28 EP EP01919406A patent/EP1272190A2/en not_active Withdrawn
- 2001-03-28 AU AU2001246518A patent/AU2001246518A1/en not_active Abandoned
- 2001-03-28 WO PCT/EP2001/003551 patent/WO2001074364A2/en not_active Application Discontinuation
Non-Patent Citations (5)
Title |
---|
BRODATY H.: "Galanthamine." DRUGS AND AGING, (1996) 9/1 (66-67). , XP001022490 * |
NORDBERG, AGNETA ET AL: "Cholinesterase inhibitors in the treatment of Alzheimer 's disease: a comparison of tolerability and pharmacology" DRUG SAF. (1998), 19(6), 465-480 , XP001037505 * |
RAINER, M. ET AL: "Long-term cognitive benefit from galanthamine in Alzheimer 's disease" INT. J. GERIATR. PSYCHOPHARMACOL. ( 1998 ), 1(4), 197-201 , XP001022883 * |
See also references of EP1272190A2 * |
THATTE, URMILLA: "Galantamine Sanochemia Pharmazeutika AG" CURR. OPIN. CENT. PERIPHER. NERV. SYST. INVEST. DRUGS ( 1999 ), 1(3), 357-372 , XP001022937 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001074339A2 (en) * | 2000-04-03 | 2001-10-11 | Janssen Pharmaceutica N.V. | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
WO2001074339A3 (en) * | 2000-04-03 | 2002-09-12 | Janssen Pharmaceutica Nv | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
EP2213285A2 (en) * | 2003-12-19 | 2010-08-04 | Novartis AG | Use of sphingosine-1-phosphate (S1P) receptor agonists in combination with a second agent for the treatment of brain degenerative diseases |
EP2213285A3 (en) * | 2003-12-19 | 2010-10-20 | Novartis AG | Use of sphingosine-1-phosphate (S1P) receptor agonists in combination with a second agent for the treatment of brain degenerative diseases |
US8519006B2 (en) | 2003-12-19 | 2013-08-27 | Novartis Ag | Use of sphingosine-1 phosphate (S1P) receptor agonists for the treatment of brain degenerative diseases |
US20180200259A1 (en) * | 2015-05-18 | 2018-07-19 | Synaptec Development Llc | GALANTAMINE CLEARANCE OF AMYLOID ß |
Also Published As
Publication number | Publication date |
---|---|
AU2001246518A1 (en) | 2001-10-15 |
CA2310990A1 (en) | 2000-10-09 |
EP1272190A2 (en) | 2003-01-08 |
WO2001074364A3 (en) | 2002-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11318144B2 (en) | Compositions and methods for treating Alzheimer's disease and Parkinson's disease | |
KR20030016205A (en) | A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders | |
Chase et al. | Donepezil plus solifenacin (CPC-201) treatment for Alzheimer's disease | |
KR20060109493A (en) | Combination drug therapy to treat obesity | |
US20180147193A1 (en) | Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions | |
JP2007526335A (en) | 1-Aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially behavioral disorders associated with Alzheimer's disease | |
WO2021262196A1 (en) | Compositions and methods for treating alzheimer's disease and parkinson's disease | |
US6086914A (en) | Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity | |
JP2014520856A (en) | Combined ALS therapy | |
US6835728B2 (en) | Drug combination for the treatment of depression and related disorders comprising mirtazapine | |
JPS63243028A (en) | Antidepressant for alleviating basic depression | |
US20030139391A1 (en) | Efficacious dosage regimen of galantamine that reduces side effects | |
EP1272190A2 (en) | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease | |
US20130012483A1 (en) | Novel pharmaceutical composition for the treatment of neurodegenerative or neurovascular diseases | |
KR20060020664A (en) | Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight | |
KR100692235B1 (en) | New use of angiotensin ii antagonists | |
AU2001265844A1 (en) | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease | |
WO2001074339A2 (en) | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease | |
IL230174A (en) | Pharmaceutical composition for treating premature ejaculation | |
KR20050096147A (en) | Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders | |
JP2593910B2 (en) | Agent for preventing or suppressing panic disorder | |
EP1569650B1 (en) | Use of levocetirizine for the treatment of persistent allergic rhinitis | |
US20240050427A1 (en) | Treatments for obsessive compulsive disorder | |
US8222278B2 (en) | Treatment of attention-deficit/hyperactivity disorder | |
Robert et al. | Efficacy and tolerability of ebastine 10 mg plus pseudoephedrine 120 mg in the symptomatic relief of the common cold |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001919406 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001919406 Country of ref document: EP |
|
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001919406 Country of ref document: EP |